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ABSTRACT 
Objective: Obesity has been described as a worldwide increasing health problem and risk factor of various disorders including type 2 diabetes 
mellitus (T2DM). So, our study aim to determine of common variants of fat mass and obesity associated gene polymorphisms rs1421085 and rs 
9939609; confers risk of obesity and type 2 diabetic mellitus in Egyptian females. 
Methods: In this population rs1421085 and rs9939609 polymorphisms of fat mass and obesity (FTO) gene were genotyped in 105 obese patients 
and 100 healthy controls with ages 14-60 y were collected from Medicine Specialized Hospital, Mansoura University, Egypt during the period 
between Jul.-Oct. 2016, genotyping of SNPs was performed by restriction fragment length polymorphism (RFLP) assay, fasting blood glucose, 
homeostasis model assessment of insulin resistance (HOMA IR), body mass index (BMI), waist-to-hip ratio (WHR) lipid profile was determined.  
Results: There was the significantly higher frequency of the AA compared to controls p=0.0001) of genotypers9939609. Also, cases have shown a 
significantly higher frequency of the C allele, p<0.00001) of rs1421085 genotype polymorphisms increased the risks of obesity. On the other hand, 
there were no significant correlations between genotypes and obesity-related (anthropometric body composition) parameters. Only the fasting 
blood glucose was significantly higher in the TA p=0.004).  
Conclusion: The FTO rs9939609 and rs1421085 single nucleotide polymorphisms (SNPs) was associated with increased risk of obesity in type 2 
diabetic populations on Egyptian females. 
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FTO gene was assigned to chromosome 16 at position 12.2 [1]. FTO 
has a total length of 410509 bp and contains nine exons and several 
nucleotide polymorphisms [2]. 
The fact that high levels of FTO expression are found in the brain, 
specifically in the accurate nucleus of the hypothalamus, which is known 
to play a major role in controlling energy homeostasis and eating 
behaviour, together with new insights from recent in vitro studies 
indicating a possible role in energy expenditure, provides support for a 
role of FTO in the explanation of obesity development [3, 4]. 
Obesity is considered a medical condition involving an accumulation 
of excess body fat potentially posing a threat to health and life of an 
individual. The prevalence of obesity is increasing worldwide in both 
developing and developed countries. It has become a serious 
epidemic health problem, estimated to be the fifth leading cause of 
modality at global level [5-9]. On the other hand, studies in Chinese 
Han [10], Oceanic [11], and African populations [12] failed to 
confirm rs9939609 variant as a major contributor to obesity and 
type 2 diabetic (T2D). Studies in Korean, Malay, Japanese, Canadians 
of South Asian origin, and Chinese populations have reported the 
association of this SNP with BMI and obesity [13-19]. Despite less 
frequency of risk allele A in the Chinese population, its effect on BMI 
was the same as that in the European population [13]. FTO variant 
associated strongly with T2D but weakly with obesity in Indians 
[20]. In short, the disease association of the FTO variant varies with 
ethnicity and populations. 
To determine whether FTO gene is a genetic risk factor for 
developing obesity in Egyptian females, we analyzed rs1421085 and 
rs9939609 polymorphisms in patients with T2DM, diabetic obesity 
and healthy controls. Besides, the relationship between FTO gene 
polymorphisms and obesity is discussed in the manuscript. 
MATERIALS AND METHODS 
Limitation of the study 
This work based on 105 cases (after taking their approved) representing 
obeses cases and obese diabetic cases; 55 cases obese only. Their mean 
age±SD 36.07±10, range of 14–61 y and 50 cases presenting diabetic 
obeses with mean age±SD 38.94±11 and comparing with 100 healthy 
control are collecting from the central area of Nile Delta of Egypt from 
the Department Obesity and Diabetes International Medicine Specialized 
Hospital, Mansoura University, Egypt, and comparing cases to their 
complication with length, weight, cholesterol triglycerides, low density 
liprotien (LDL), high density liprotien (HDL), glycated homoglopein 
average of plasma glucose concentration (HbA1c), fasting blood glucose 
(FBG), Insulin, Homa IR, BMI. For all cases and controls; DNA extraction 
was carried out followed by PCR detection of their rs 1421085 and 
9939609 genetic polymorphism. 
Measurement of anthropometric parameters  
Body weight, height, waist and hip circumference, systolic blood 
pressure (SBP), and diastolic blood pressure (DBP) were measured 
according to the standard procedures [21]. Body height was measured 
using a wall-mounted stadiometer, and body weight was measured using 
a digital scale. BMI of each subject was calculated. Waist circumference 
was measured just above navel midway between the lower margin of the 
last rib and iliac crest to the nearest 0.1 cm. Hip circumference was taken 
as the maximal circumference over the buttocks. Waist-to-hip ratio was 
calculated from the values of waist and hip circumference. DBP was 
measured twice from the right arm of the subject in a sitting position 
using a standard mercury sphygmomanometer. 
Measurement of metabolic parameters 
Blood samples were drawn after an overnight fast of 8–12 h. Fasting 
blood glucose (FBG) levels were determined by the glucose oxidase 
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method using HumaStar 180 chemistry analyzer (Human, 
Wiesbaden, Germany). Concentrations of plasma insulin, leptin, and 
leptin receptors were determined by ELISA using the commercial kit 
with an automated EIA analyzer (Bio-Rad Laboratories, Hercules, 
CA, USA). FBG and fasting insulin levels were used to measure 
homeostasis model assessment of insulin resistance (HOMA-IR) 
calculated by the following formula: HOMA-IR = Fasting insulin 
(IU/ml) × Fasting glucose (mmol/l)/22.5 [22]. 
DNA extraction and genotyping 
Genomic DNA was extracted from whole blood using genomic DNA 
purification kit (Fermentas, USA). Genotyping of rs9939609 
polymorphism at FTO locus was carried out by polymer as a chain 
reaction-restriction fragment length polymorphism assay (PCR-RFLP). A 
DNA fragment containing rs9939609 polymorphism was amplified using 
specific primers (forward primer sequence: AACTGGCTCT-
TGAATGAAATAGGATTCAGA and reverse primer sequence: AGAGTA-
ACAGAGACTATCCAAGTGCAGTAC). The PCR was carried out using 
thermocycler (Icycler 5, BioRad, USA) according to the optimized 
conditions. In 25 L reaction, PCR components comprised of 50 ng DNA, 
1X Taq buffer, 2 mmol MgCl2, 200 M of each dNTP, 10 mol of each 
primer, and 1U Taq DNA polymerase. Thermal cycling was performed as 
follows: initial denaturation at 95 °C for 4 min, followed by 35 cycles of 
denaturation at 94 °C for 30 sec, annealing at 58 °C for 30 sec and 
extension at 72 °C for 1 min, and then a final extension step at 72 °C for 
10 min. Amplified products were digested with Sca1 restriction enzyme 
(Favorgen, Taiwan) to analyze for polymorphism by RFLP assay 
polymorphisms of primers of the rs1421085 T>C polymorphism were 5-
GGCAGACTTGTAAGGAACAAGA-3 (forward) and 5-AAATTCT-CATCAGA-
CACTTAATCGAT-3 (reverse) which generated the 127-bp fragment. For 
the rs1421085 T>C variant, the expected fragment sizes were 101-and 
26-bp for the ECO32I restriction site. The PCR profile for the rs1421085 
T>C polymorphism consisted of an initial melting step of 95 °C for 5 min; 
35 cycles of 95 °C for 30s, 51 °C for 40s and 72 °C for 40s and a final step 
of 72 °C for 10 min. 
Statistical analysis 
The data were analyzed using Statistical Package for Social Sciences 
(SPSS Inc. Chicago, IL, USA, version 17.0). Quantitative variables 
were expressed as mean±standard error (SE). Student’s -test was 
applied to observe the differences between case and control groups. 
The whole data were stratified according to age in subgroups. Hardy 
Weinberg equilibrium test (HWE) was applied to determine the 
variation in distribution of alleles and genotypes within the 
concerned population. Allelic frequencies were calculated by gene 
counting. Chi-square (2) test was used to determine the significant 
differences of genotype and allelic frequencies between obese and 
nonobese groups. Association of rs9939609 and the 
rs1421085variant with obesity was determined by Pearson Chi-
square using codominant, dominant and recessive models. Odds 
ratio (OR) and 95% confidence interval (CI) were calculated to 
determine the risk of obesity associated with the risk allele. The 
association of FTO rs9939609 variant with anthropometric and 
metabolic traits was determined using General Linear Model (GLM) 
assuming codominant, dominant, and recessive genetic models. The 
genotypes were coded as (0, 1, 2) in codominant model, (0, 1) in 
dominant model and (1, 0) in recessive model corresponding to the 
number of copies of risk allele. 
RESULTS 
By comparing demographic and laboratory data of obese cases 
compared to controls (table 1) shows demographic and laboratory 
data of obese cases compared to controls. All parameters showed 
significant higher values in cases compared to controls (p<0.05) 
except for the waist hip ratio (WHR). On the other hand, the 
demographic and laboratory data of obese diabetic cases compared 
to controls (table 1) shows demographic and laboratory data of 
obese diabetic cases compared to controls. All parameters showed 
significant higher values in cases compared to controls (p<0.05) 
except for the waist-hip ratio and LDL levels (p>0.05). 
The demographic and laboratory data of obese non-diabetic cases 
compared to controls shows demographic and laboratory data of 
obese non-diabetic cases compared to controls. Values 
corresponding to length, weight, cholesterol, triglycerides, LDL, 
insulin, Homa IR, waist, hip and BMI were significantly higher in 
cases compared to controls (p<0.05); whereas both groups showed 
no significant difference regarding their age, waist-hip ratio, FBG 
and HbA1C (p>0.05). 
 
Table 1: Demographic and laboratory data of obese and obese diabetic cases compared to controls 
 Controls+ Obese++ Obese Diabetic+++ 
Mean ±SD Mean ±SD p Mean ±SD p 
Age 31.88 11.066 36.07 10.870 .007* 38.94 11.083 .000** 
Length 165.14 10.956 159.38 6.077 .000** 158.36 7.631 .000** 
Weight 72.20 56.719 105.47 13.024 .000** 108.20 9.282 .000** 
Cholesterol 171.98 12.367 202.71 43.770 .000** 202.18 41.621 .000** 
Triglyceride 82.12 20.873 137.33 52.406 .000** 151.40 47.398 .000** 
HDL 41.64 5.268 44.43 12.413 .039* 49.66 14.349 .000** 
LDL 119.70 19.414 133.77 42.481 .003* 120.99 39.190 .787 
HbA1c 5.10 .518 7.15 4.931 .000** 8.05 1.515 .000** 
FBG 95.43 7.175 119.44 32.136 .000** 146.56 26.038 .000** 
Insulin 5.42 1.585 22.39 4.627 .000** 19.95 4.942 .000** 
Homa IR 1.15 .390 5.73 1.127 .000** 6.35 1.239 .000** 
Waist 66.04 9.147 102.48 7.941 .000** 103.68 6.747 .000** 
Hip 79.04 8.888 112.29 8.092 .000** 113.72 6.725 .000** 
WHR .95 1.169 .91 .014 .717 .91 .006 .798 
BMI*** 24.32 1.606 41.66 5.739 .000** 43.42 5.639 .000** 
+n = 100,++n = 55,+++n = 50, * = p-value<0.05, ** = p-value<0.001, ***BMI: body mass index (%). Data presented mean±SD. 
 
The frequency of FTO rs9939609 polymorphic forms in total obese 
cases compared to controls adjusted by age (table 2) shows the 
frequency of FTO rs9939609 polymorphic genotypes in total obese 
cases compared to controls adjusted by age. Obese cases showed 
significantly higher frequency of the AA genotype compared to 
controls in the codominant model (21.9% vs. 4%, p=0.0001). Also, 
observed in the recessive model (p=0.0001). However, cases showed 
a significantly lower frequency of TA genotype in the overdominant 
model (35.2% vs. 60%, p=0.00026). 
The Frequency of FTO rs9939609 polymorphic forms in total obese 
cases compared to controls adjusted by diabetes and age (table 2) shows 
the frequency of FTO rs9939609 polymorphic genotypes in total obese 
cases compared to controls adjusted by age and diabetes. Obese cases 
still, showed significantly higher frequency of the AA genotype compared 
to controls in the codominant model (21.9% vs. 4%, p=0.012). This was 
also observed in the recessive model (p=0.0039). 
The results of FTO rs9939609 exact test for Hardy-Weinberg 
equilibrium shows exact test for Hardy-Weinberg equilibrium in 
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all studied subjects as well as each separate group. Regarding 
the groups of all participants, the test showed the non-significant 
difference between the observed and expected frequencies for 
polymorphic genotypes i.e. coping with the genetic equilibrium. 
On the contrary, regarding each individual group of controls and 
cases, each was significantly departing from the equilibrium 
probably due to the high values of AA in cases and TA in 
controls. 
 
Table 2: Frequency of FTO rs9939609 polymorphic forms in total obese cases compared to controls adjusted by diabetes and age 
Model Genotype Controls+ Obese Obese cases++ Obese-diabetic cases+++ 
OR (95% CI) p-value OR (95% CI) p-value 
Codominant T/T 36 (36%) 45 (42.9%) 1.00 0.0001** 1.00 0.0001** 
T/A 60 (60%) 37 (35.2%) 0.58 (0.31-1.07) 0.58 (0.31-1.07)  
A/A 4 (4%) 23 (21.9%) 4.99 (1.55-16.06) 4.99 (1.55-16.06)  
Dominant T/T 36 (36%) 45 (42.9%) 1.00 0.65 1.00 0.65 
T/A-A/A 64 (64%) 60 (57.1%) 0.87 (0.49-1.57) 0.87 (0.49-1.57)  
Recessive T/T-T/A 96 (96%) 82 (78.1%) 1.00 0.0001** 1.00 0.0001** 
A/A 4 (4%) 23 (21.9%) 6.80 (2.22-20.90) 6.80 (2.22-20.90)  
Over dominant T/T-A/A 40 (40%) 68 (64.8%) 1.00 0.0026* 1.00 0.0026* 
T/A 60 (60%) 37 (35.2%) 0.41 (0.23-0.74) 0.41 (0.23-0.74)  
Alleles T 132 (66%) 127 (60%) 1.27 (0.8-1.9) 0.29 1.27 (0.8-1.9) 0.29 
A 68 (34%) 83 (40%)     
+n = 100,++n = 55 and+++n = 50. 
 
On the other hand, the frequency of FTO rs1421085 polymorphic 
genotypes in total obese cases compared to controls adjusted by age 
shows the frequency of FTO rs1421085 polymorphic genotypes in total 
obese cases compared to controls adjusted by age. Obese cases showed 
significantly higher frequency of the CC genotype compared to controls 
(29.5% vs. 3%, p<=0.0001). This was also observed but to a lesser degree 
for the CT genotype (37.1% vs. 29%, 4.89, p=0.0001) in the codominant 
model. This was also observed in the recessive model for the CC 
genotype (p=0.0001) and in the dominant model for the CT+CC 
genotypes (66.7% vs. 32%, p=0.0001). Cases have also shown a 
significantly higher frequency of the C allele (48% vs. 18%, OR=4.37, 
95%CI=2.8-6.8, p<0.00001). 
The Frequency of FTO rs1421085 polymorphic forms in total obese 
cases compared to controls adjusted by diabetes and age shows the 
frequency of FTO rs1421085 polymorphic genotypes in total obese cases 
compared to controls adjusted by age and diabetes. Obese cases showed 
significantly higher frequency of the CC genotype compared to controls 
(29.5% vs. 3%, p<=0.0001). This was also observed but to a lesser degree 
for the CT genotype (37.1% vs. 29%, p=0.0001) in the codominant 
model. The same was also observed in the recessive model for the CC 
genotype (p=0.0001) and in the dominant model for the CT+CC 
genotypes (66.7% vs. 32%, p=0.0001). Cases have also shown a 
significantly higher frequency of the C allele (48% vs. 18, p<0.00001). 
Hardy-Weinberg equilibrium in all studied subjects as well as each 
separate group, regarding the control group, the test showed non-
significant difference between the rs1421085 exact tests for Hardy-
Weinberg equilibrium shows exact test for observed and expected 
frequencies for polymorphic genotypes i.e. coping with the genetic 
equilibrium. On the contrary, regarding the group of cases and in all 
participants, the test was significantly departing from the 
equilibrium probably due to the high values of CC and CT in cases. 
Significantly, higher frequency of the FTO rs9939609 A and 
rs1421085 C haplotype compared to controls (22.1% vs. 6.11%, 
OR=4.40, 95% CI=2.09-9.3, p=0.0001 adjusted by age, OR=4.70, 95% 
CI=2.02-10.93, p=0.0004 adjusted by age and diabetes). 
The laboratory parameters related to lipid profile (table 3) and 
blood sugar in all obese cases regarding their FTO rs9939609 gene 
polymorphic types shows laboratory parameters related to lipid 
profile and blood sugar in all obese cases regarding their FTO 
rs9939609 gene polymorphic types. Cases showed no significant 
difference for all values of lipid profile (cholesterols, triglycerides, 
HDL and LDL) as well as laboratory tests of diabetes (HbA1c, FBG, 
insulin and Homa IR) related to their polymorphic genotypes, also 
no significant BMI and WHR related to their polymorphic 
genotypes. 
 
Table 3: Parameters related to lipid profile and blood sugar in all obese cases regarding their FTO rs9939609 and rs1421085 gene 
polymorphism 
 rs9939609 rs1421085 
Genotype N Mean ±SD P (TT vs TA) Genotype N Mean ±SD P (TT vs TC) 
Cholesterol T/T 24 206.92 43.411 .955 T/T 35 200.17 39.212 .941 
T/A 12 206.08 36.592  T/C 39 199.51 37.572  
A/A 14 190.71 43.187  C/C 31 209.61 55.143  
Triglycerides T/T 24 155.29 53.179 .435 T/T 35 144.46 58.506 .723 
T/A 12 141.83 35.680  T/C 39 139.92 51.175  
A/A 14 152.93 47.671  C/C 31 126.02 46.085  
HDL T/T 24 51.25 15.840 .858 T/T 35 42.83 11.703 .313 
T/A 12 50.33 10.790  T/C 39 45.67 12.233  
A/A 14 46.36 14.726  C/C 31 44.68 13.578  
LDL T/T 24 126.46 41.455 .391 T/T 35 137.03 53.139 .542 
T/A 12 113.95 39.048  T/C 39 130.55 37.144  
A/A 14 117.64 36.679  C/C 31 134.13 35.808  
HbA1c T/T 24 8.03 1.336 .759 T/T 35 6.55 1.533 .441 
T/A 12 8.18 1.557  T/C 39 6.86 1.875  
A/A 14 7.99 1.851  C/C 31 8.18 8.691  
FBG T/T 24 139.50 15.795 .004* T/T 35 117.03 31.831 .291 
T/A 12 165.25 35.327  T/C 39 124.97 32.360  
A/A 14 142.64 25.040  C/C 31 115.19 32.252  
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Insulin T/T 24 20.45 4.949 .093 T/T 35 23.47 4.915 .091 
T/A 12 17.46 4.823  T/C 39 21.67 4.114  
A/A 14 21.21 4.598  C/C 31 22.10 4.826  
Homa IR T/T 24 6.34 1.448 .671 T/T 35 5.91 1.268 .670 
T/A 12 6.14 .898  T/C 39 5.80 .960  
A/A 14 6.55 1.144  C/C 31 5.44 1.130  
BMI T/T 24 43.54 4.850 .984 T/T 35 40.52 3.632 .228 
T/A 12 43.59 8.774  T/C 39 41.67 4.408  
A/A 14 43.06 3.595  C/C 31 42.93 8.452  
WHR T/T 24 .91 .005 .233 T/T 35 .92 .022 .177 
T/A 12 .91 .008  T/C 39 .91 .007  
A/A 14 .91 .004  C/C 31 .91 .007  
N = number of cases. Data presented mean±SD. * = p-value. 
 
The laboratory parameters related to lipid profile and blood sugar in 
all (table 3) obese diabetic cases regarding their FTO rs9939609 
gene polymorphic type’s shows laboratory parameters related to 
lipid profile and blood sugar in all obese diabetic cases regarding 
their FTO rs9939609 gene polymorphic types. Cases showed no 
significant difference for all values of lipid profile (cholesterols, 
triglycerides, HDL and LDL) as well as laboratory tests of diabetes 
(HbA1c, insulin and Homa IR) related to their polymorphic 
genotypes. Only the fasting blood glucose was significantly higher in 
the TA genotype than that of the TT genotype. 
On the other hand, Laboratory parameters related to lipid profile 
and blood sugar in all obese cases regarding their FTO rs1421085 
gene polymorphic types shows laboratory parameters related to 
lipid profile and blood sugar in all obese cases regarding their FTO 
rs1421085 gene polymorphic types. Cases showed no significant 
difference for all values of lipid profile (cholesterols, triglycerides, 
HDL and LDL) as well as laboratory tests of diabetes (HbA1c, FBG, 
insulin and Homa IR) related to their polymorphic genotypes. 
Finally, the laboratory parameters related to lipid profile and blood 
sugar in all obese diabetic cases regarding their FTO rs1421085 gene 
polymorphic types shows laboratory parameters related to lipid 
profile and blood sugar in all obese diabetic cases regarding their FTO 
rs1421085 gene polymorphic types. Cases showed no significant 
difference for all values of lipid profile (cholesterols, triglycerides, HDL 
and LDL) as well as laboratory tests of diabetes (HbA1c, FBG, insulin 
and Homa IR) related to their polymorphic genotypes. 
DISCUSSION 
The first FTO polymorphisms associated with obesity were identified 
through a genome-wide association (GWA) study searching for novel 
genes associated with type-2 diabetes in diabetic cases and population 
controls from the Welcome Trust Case Control Consortium in the 
United Kingdom [23, 24]. Our study aims mainly to chock for the 
association of FTO gene rs 1421085 and rs 9939609 genes on obesity 
cases and diabetic obeses (T2DM) cases in Egyptian female. 
In the first part of our study we have compared of FTO rs 9939609 
polymorphic forms in total obese cases compared to controls and 
adjusted by age we showed significantly higher frequency of the AA 
genotype compared to controls (p = 0.0001). 
Also, it is found a strong association in total obese cases compared to 
control adjusted by diabetes and age was showed significantly 
frequency of AA genotype compared with controls (p = 0.012). 
On the other hand, our study did not appear to influence any lipid 
parameter in the subject tested include (cholesterol, Trighcerds HDL 
and LDL) as well as laboratory tests of diabetes (HbA1C, FBG, insulin 
and Homa IR) in all obese cases of FTO rs 9939609 gene. Only rs FTO 
9939609 gene showed fasting blood glucose was significantly higher 
in TT genotype than TA genotype, p = 0.04%). Therefore, our study 
reported that strong association of FTO rs 9939609 and T2DM. Also, 
there is no significant of BMI and WHR in this study of FTO rs 
9939609 gene polymorphism in obases and obases diabetic case 
adjusted by age. Our data are in agreement with [25] reported that 
spatial analysis and meta-analysis showed an association between 
genetic polymorphism FTO 9939609 and T2DM. Also, showed that 
rs 9939609 was associated with T2DM risk somewhat independent 
BMI in East and South Asia population. 
On the other hand, our study did not in agreement with Europe and 
the American population for FTO rs 9939609 polymorphism and 
there was an association between genetic polymorphism T2DM risks 
somewhat dependent BMI. 
Our data showed not in agreement within the Chinese population 
[10] showed that FTO rs 9939609 genotype was not found to be 
associated with obesity overweight BMI, circumference or body fat. 
This is may be due to limited lifestyle or age. 
Also, in adult Pakistan female population, [26] reported that 
association of rs 9939609 polymorphism variant of FTO gene in 
adult Pakistan female with BMI and obesity with measure of body fat 
distribution such as waist circumference, but our data in accordance 
with suggest the role of this polymorphism in fat deposition and 
predisposing factor for obesity, association of rs 9939609 variant of 
FTO gene with higher fasting blood sugar predispose to T2DM. 
There was no increased risk of obesity in term of rs 9939609 
polymorphism on their study on Cobort of Swedish men born 1920-
1924 [27]. 
Additionally, [28] noted that the FTO rs 9939609 variant was 
associated with increase BMI adjusted for age beside Aalle of rs 
9939609 polymorphism has been associated with increased risk to 
best-developing obesity. 
Also, [29] note find an association of rs 9939609 with neither birth 
weight nor weight again in very low birth weight infant. 
Our study similarly within Pakistan population Our study similarly 
[30] reported that FTO9939609 gene is associated with obesity and 
showed for the first time in Pakistan with cornary artery disease to 
influence any lipid parameter in the subject tested, however, show a 
consistent association with blood glucose level. Therefore, it might 
play a role in progression to cornary artery disease through effecting 
plasma glucose metabolism.  
This is according with a recent meta-analysis which reported that 
this variant has no correlation with serum lipid chemistry and is 
associated with glucose [31]. 
Other studies have found an interaction between the FTO rs 
9939609 genotype and physical activity and reported that physically 
interactive homozygous risk. Allel carries has a 1.95±0.3 kg/m2 
increase in BMI compared with homozygous T allel and obesity. This 
is related to quantitative trails such as body weight waist 
circumference, fat mass was significantly with allel carrier [32]. 
On the other hand our data also noted by comparing of FTO rs 
1421085 polymorphic forms in total obese cases compared to 
controls adjusted by diabetic and age. We showed significantly 
higher frequency of the CC genotype compared with controls (p<= 
0.0001). 
Also, all cases shown significantly higher frequency of C allel 
(p<0.00001) of FTO rs 1421085 polymorphic form in total cases 
compared to controls adjusted by diabetes and age was increase risk 
of obesity and T2DM BMI and WHR independently.  
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Also, we have compared of lipid profile and blood sugar in all obeses 
cases to their FTO rs 1421085 polymorphic gene type. Our data 
showed parameter related to lipid profile there was no significant 
difference as well as testes of diabetes (HbAic, FBG, insulin and 
Homa IR). 
Our studies showed no significant difference by comparing lipid 
profile and blood sugar in all obese diabetic cases to their FTO rs 
1421085 gene polymorphism.  
In addition to that our study found an association of FTO gene 
1421085 polymorphism and high lights the possible role of obesity 
and DT2M type 2 diabetes and its correlation with higher fasting 
glucose independently from BMI and WHR on Egyptian female. This 
is may be due to limited lifestyle or age. The1421085 C allel was 
significantly associated with increase BMI was reported in Korean 
population [15]. 
Our data showed in agreement with Tunisian population [33] 
reported the association of FTO gene 1421085 polymorphism and 
high lights the possible role gene as a predictor of cardiovascular 
disease and T2DM and it correlation with higher fasting glucose 
independently from BMI. Other studies have shown in the Chinese 
population [34] say there no significant association between FTO 
variant of rs 1421085 genotype and obesity and level TC, TG, HDL 
and LDL were not found to be significantly associated with obesity. 
Also, our data showed not agreement with European population, 
[11] reported that no significant association between FTO 
polymorphism includes 1421085 and BMI. 
Our data also showed not in agreement with European population, 
[25] reported that spatial analysis showed studies on rs 1421085 in 
scarce and have limited regional coverage, lake of association due to 
smaller sample size and less studies. 
There was no significant relationship has been reported between 
FTO gene polymorphism rs 9939609 and rs 1421085 and BMI in 
Turkey population [35], similarly rs 9939609 polymorphism and 
obesity was not associated with obesity [36]. 
Also, protuyuses children population, [37] found a significant 
association of rs9939609 and rs 1421085 polymorphism with weight, 
BMI, BMI 2-score waist circumference and hip circumference. 
CONCLUSION 
Finally, the present study was the first that reports the association of 
FTO gene polymorphism with obesity and T2DM and its correlation 
with higher fasting blood glucose also shown significant higher 
frequency of C allele which increases the risk of obesity. On the other 
hand, there was no significant correlation between genotype and 
obesity-related (anthropotemtric body composition) parameter.  
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